SuperworthMBX Biosciences EPS MBX
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$2.40
- Latest quarter, Q2 FY26
- −$0.78
- Fiscal year 2025
- −$2.41
MBX Biosciences' earnings per share was −$2.40 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.78.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.41 | n/a |
| FY2023 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.78 | n/a | −$2.40 | |
| Q1 FY26 | −$0.50 | n/a | −$2.20 | |
| Q4 FY25 | −$0.49 | n/a | −$2.41 | |
| Q3 FY25 | −$0.63 | n/a | n/a | |
| Q2 FY25 | −$0.58 | n/a | n/a | |
| Q1 FY25 | −$0.71 | n/a | n/a | |
| Q3 FY24 | −$2.78 | n/a | −$33.40 | |
| Q2 FY24 | −$12.62 | n/a | −$40.02 | |
| Q1 FY24 | −$10.26 | n/a | n/a | |
| Q4 FY23 | −$7.74 | n/a | n/a | |
| Q3 FY23 | −$9.40 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest MBX Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MBXMBX Biosciences | −$2.40 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| OGNOrganon | $0.77 | −71% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on MBX Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.